07:05 AM EST, 12/04/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Wednesday its Surmount-5 phase 3b clinical study showed that Zepbound provided a 47% "greater relative weight loss" in comparison to Novo Nordisk's ( NVO ) Wegovy.

Zepbound, Eli Lilly's ( LLY ) weight-loss drug, resulted in a "superior" weight reduction of 20.2% against Wegovy's 13.7%, the company added.

Eli Lilly's ( LLY ) stock rose 2.3% in recent Wednesday premarket activity, while Novo Nordisk's ( NVO ) shares were little changed.